Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer’s Dementia (R21 Clinical Trial Optional)
Can you apply?
This grant is for researchers and research institutions seeking funding to investigate novel mechanisms underlying neuropsychiatric symptoms (NPS) in Alzheimer's dementia. Eligible applicants include academic institutions, research hospitals, independent research organizations, nonprofit organizations, and small businesses that can conduct clinical research. The program supports exploratory research, including optional clinical trial components, across the United States. Activities supported include hypothesis-driven basic or clinical research investigating new approaches to understanding NPS in Alzheimer's disease, novel biomarkers, mechanistic studies, and pilot clinical trials. International collaborations are permitted. The R21 mechanism is designed for early-stage exploratory research with relatively limited budgets and project periods, making it ideal for proof-of-concept work and novel research directions.
This grant is for researchers and research institutions seeking funding to investigate novel mechanisms underlying neuropsychiatric symptoms (NPS) in Alzheimer's dementia. Eligible applicants include academic institutions, research hospitals, independent research organizations, nonprofit organizations, and small businesses that can conduct clinical research. The program supports exploratory research, including optional clinical trial components, across the United States. Activities supported include hypothesis-driven basic or clinical research investigating new approaches to understanding NPS in Alzheimer's disease, novel biomarkers, mechanistic studies, and pilot clinical trials. International collaborations are permitted. The R21 mechanism is designed for early-stage exploratory research with relatively limited budgets and project periods, making it ideal for proof-of-concept work and novel research directions.
Program description
The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer’s disease (AD) or Alzheimer’s disease-related dementias (ADRD). The findings are expected to advanceadavnce mechanistic understanding of both biobehavioral and neurobiologfical pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- County Government
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
Demographic focus
Details
This grant is for researchers and research institutions seeking funding to investigate novel mechanisms underlying neuropsychiatric symptoms (NPS) in Alzheimer's dementia. Eligible applicants include academic institutions, research hospitals, independent research organizations, nonprofit organizations, and small businesses that can conduct clinical research. The program supports exploratory research, including optional clinical trial components, across the United States. Activities supported include hypothesis-driven basic or clinical research investigating new approaches to understanding NPS in Alzheimer's disease, novel biomarkers, mechanistic studies, and pilot clinical trials. International collaborations are permitted. The R21 mechanism is designed for early-stage exploratory research with relatively limited budgets and project periods, making it ideal for proof-of-concept work and novel research directions.
How to apply
Application links
Required documents
- SF-424 (R&R) form and project narrative (NIH-specific format)
- Research plan (specific aims, significance, innovation, approach, timeline)
- Biographical sketches of key personnel (NIH format)
- Budget and budget justification
- Letters of support or institutional endorsement
- Preliminary data and feasibility evidence
- IRB/IND documentation (if clinical trial component proposed)
- Data management and safety plan (if applicable)
- Publication or patent records demonstrating prior research output
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.866 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$463,372,200
-
$172,327,224
-
$115,145,694
-
$99,649,073
-
$93,275,174
-
$78,657,309
-
$75,825,492
-
$75,398,895
-
$70,985,470
-
$64,812,576
Top States by Funding
- MI 2 awards $511.9M
- CA 8 awards $511.1M
- MO 8 awards $437.0M
- IN 4 awards $303.9M
- PA 6 awards $298.0M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.866). How funding has trended year over year.
| 2024 | $3,746,886,731 | |
| 2025 | $3,777,464,644 | |
| 2026 est. | $261,814,471 |
FAQ
Who is eligible to apply for this R21 grant?
Eligible applicants include research institutions (universities, hospitals, laboratories), nonprofit organizations, small businesses, and certain government organizations capable of conducting clinical research. Foreign organizations may apply with NIH-approved international subcontracts.
What is the typical funding range and project period?
R21 grants typically provide up to $275,000 in total costs over a 2-year project period, though budgets can vary. This is exploratory funding designed for early-stage research.
Can I propose a clinical trial with this grant?
Yes. The R21 mechanism indicates "Clinical Trial Optional," meaning you can propose a clinical trial component, but it is not required. If proposing a trial, follow NIH Clinical Trial requirements and budget accordingly.
What types of research activities are supported?
The program supports novel mechanistic research on neuropsychiatric symptoms in Alzheimer's dementia, including biomarker studies, therapeutic exploration, and early-stage pilot testing. Research should focus on new or underexplored mechanisms.
How competitive is this grant?
R21 mechanisms are competitive but often receive slightly higher success rates than R01 grants because they target earlier-stage work. Strong preliminary data, clear innovation, and a well-designed feasibility plan improve competitiveness significantly.
💡 Tips for applicants
- Focus on novelty and mechanism: Emphasize what is new about your approach to understanding NPS in Alzheimer's. Review recent literature to clearly position your work against existing knowledge and show the gap you will fill.
- Pilot data matters: Even for exploratory R21 research, some preliminary evidence strengthens your application. Include proof-of-concept data, feasibility studies, or compelling background data to support your approach.
- Be realistic about scope: R21 grants have limited budgets and 2-year timelines. Clearly demonstrate that your specific aims are achievable within these constraints and that you've carefully scaled your ambitions accordingly.
- If including a clinical trial: Specify whether yours is a Phase I, Phase IIA, or feasibility trial. Detail recruitment strategy, inclusion/exclusion criteria, sample size justification, and IRB/regulatory timeline.
- Address NPS specifically: Neuropsychiatric symptoms (agitation, depression, anxiety, psychosis, etc.) are distinct from cognitive decline. Be clear which NPS symptoms you're studying and why they are therapeutically important targets.
⚠️ Common mistakes
Many R21 applications fail because they lack clear innovation or present incremental extensions of prior work rather than genuinely novel mechanisms. Additionally, applicants often propose overly ambitious scope for a 2-year exploratory grant; the key is demonstrating that your specific aims are feasible and focused on proof-of-concept, not a full-scale trial or comprehensive clinical program.
Similar grants
- OPEN 27-0343-10 FFY27 Local Agency General Non-Enforcement — Illinois Department of Transportation
- ROLLING Annual Agency Threshold Application Applicants for Funding Start Here — Texas City of Austin - Austin Public Health
- CLOSED Virginia’s Black Indigenous and People of Color (BIPOC) Grant – FY26 — Virginia The Virginia Department of Historic Resources
- ROLLING RTAP Grant Program (Rolling) — Virginia Department of Rail and Public Transportation
- ROLLING Rail Industrial Access Grant (RIA) — Virginia Department of Rail and Public Transportation